Routine vaccination with polysaccharide meningococcal vaccines is an ineffective and possibly harmful strategy

Bulletin of the World Health Organization

Volumn 81, Issue 10, 2003, Pages 751-752

  Birmingham, M E ^a   Lewis, R F ^a   Perea, W ^a   Nelson, C B ^a   Kabore, A ^b   Tarantola, D ^a  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

^b WHO Regional Office for Africa   (Zimbabwe)

Author keywords

[No Author keywords available]

Indexed keywords

MENINGOCOCCUS VACCINE; POLYSACCHARIDE VACCINE;

STRATEGIC APPROACH; VACCINATION;

BACTERIAL STRAIN; DRUG COST; EPIDEMIC MENINGITIS; EPIDEMIOLOGICAL DATA; HEALTH CARE COST; HEALTH CARE POLICY; HUMAN; NEISSERIA MENINGITIDIS; NOTE; TREATMENT OUTCOME; VACCINATION; VACCINATION REACTION; WORLD HEALTH ORGANIZATION;

EID: 0242680450     PISSN: 00429686     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (12)

1. Kaninda AV, Varaine F, Henkens M, Paquet C. Meningococcal vaccine in sub-Saharan Africa. Lancet 1997;350:1708-9.
2. Higham JH. Meningococcal vaccine in sub-Saharan Africa. Lancet 1997;350:1707-8.
3. Perkins BA, Broome CV, Rosenstein NE, Schuchat A, Reingold AL. Meningococcal vaccine in sub-Saharan Africa. Lancet 1997;350:1708.
4. Wenger J, Tikhomirov E, Barakamfitiye D, Okwo Bele, Heymann DL. Meningococcal vaccine in sub-Saharan Africa. Lancet 1997;350:1709-10.
5. World Health Organization. Detecting meningococcal meningitis epidemics in highly-endemic African countries. WHO recommendation. Weekly Epidemiologic Record 2000;75:306-9.
6. Lewis R, Nathan N, Diarra L, Belanger F, Paquet C. Timely detection of meningococcal meningitis epidemics in Africa. Lancet 2001;358:287-93.
7. Kaninda AV, Belanger F, Lewis R, Batchassi E, Aplogan A, Yakoua Y, et al. Effectiveness of incidence thresholds for detection and control of meningococcal meningitis epidemics in northern Togo. International Journal of Epidemiology 2000;29:933-40.
8. Käyhty G, Karanko V, Peltola H, Sarna S, Mäkelä PH. Serum antibodies to capsular polysaccharide vaccine of group A Neisseria meningitidis followed for three years in infants and children. Journal of Infectious Diseases 1980;142:861-8.
9. Greenwood BM, Whittle HC, Bradley AK. The duration of the antibody response to meningococcal vaccination in an African village. Transactions of the Royal Society of Tropical Medicine and Hygiene 1980;74:756-60.
10. MacLennan J, Obaro S, Deeks J, Williams D, Pais L, Carlone G, et al. Immune response to revaccination with meningococcal A and C polysaccharides in Gambian children following repeated immunization during early childhood. Vaccine 1999;17:3086-93.
11. Reingold AL, Broome CV, Hightower AW, Ajello GW, Bolan GA, Adamsbaum C, et al. Age-specific differences in duration of clinical protection after vaccination with meningococcal polysaccharide A vaccine. Lancet 1985;2:114-8.
12. World Health Organization. WHO vaccine preventable diseases: monitoring system. 2001 global summary. Geneva: 2002. WHO document WHO/V&B/02.20.